Home → Schizophrenia Treatment

Schizophrenia and Psychotic Disorders: A Psychiatrist's Guide

By Ryan S. Sultan, MD
Assistant Professor of Clinical Psychiatry, Columbia University Irving Medical Center
Board-Certified in Adult Psychiatry and Child & Adolescent Psychiatry
March 29, 2026

What Schizophrenia Actually Is

Schizophrenia is a chronic neuropsychiatric disorder characterized by disruptions in thinking, perception, emotions, and behavior. It affects approximately 1% of the global population and typically emerges in late adolescence or early adulthood (ages 16-30), though it can develop at any age.

What schizophrenia is NOT:

• It is NOT "split personality" (that is dissociative identity disorder, a completely different condition)
• It is NOT a result of bad parenting, moral failure, or weakness
• It does NOT mean someone is violent (despite media portrayals, people with schizophrenia are more likely to be victims of violence than perpetrators)
• It is NOT a hopeless condition (many people with schizophrenia live full, meaningful lives with proper treatment)

Positive Symptoms

"Positive" symptoms refer to experiences that are added to normal experience -- things that are present but should not be.

Hallucinations: Sensory experiences without an external source. Auditory hallucinations (hearing voices) are the most common, affecting approximately 70-80% of individuals with schizophrenia. The voices may be commanding, commenting, or conversational. Visual hallucinations occur in some cases. Tactile, olfactory, and gustatory hallucinations are less common but can occur.

Delusions: Fixed false beliefs that persist despite contradictory evidence. Common types include persecutory delusions (believing others are plotting against you), referential delusions (believing neutral events or comments are directed at you), grandiose delusions (believing you have special powers, are famous, or have a special relationship with a deity), and bizarre delusions (beliefs that are clearly implausible, such as alien implants or mind control).

Disorganized thinking/speech: Loosening of associations (jumping between unrelated topics), tangentiality (going off on tangents without returning to the original point), word salad (incomprehensible speech), and neologisms (made-up words).

Grossly disorganized or catatonic behavior: Unpredictable agitation, bizarre posturing, waxy flexibility (maintaining positions placed in by others), or complete immobility (catatonia).

Negative Symptoms

"Negative" symptoms refer to things that are diminished or absent from normal experience. They are often more disabling than positive symptoms and less responsive to medication.

• Flat affect (affective flattening): Reduced emotional expression in face, voice, and gestures
• Alogia: Poverty of speech -- reduced quantity and content of speech
• Avolition: Decrease in motivated, self-initiated purposeful activity (difficulty starting and completing tasks)
• Anhedonia: Reduced ability to experience pleasure from activities previously enjoyed
• Asociality: Reduced desire for social interaction

Negative symptoms are often mistaken for depression or laziness, which adds stigma to an already stigmatized condition. Understanding that these are neurobiological symptoms of the illness -- not character flaws -- is essential for patients, families, and treatment teams.

Cognitive Symptoms

Cognitive deficits in schizophrenia affect working memory, attention and concentration, processing speed, executive function (planning, organization, abstract thinking), and verbal learning and memory. These cognitive deficits are present even before the first psychotic episode (in the prodromal phase) and persist even when positive symptoms are well-controlled. They are often the strongest predictor of functional outcomes -- meaning a patient's ability to work, live independently, and maintain relationships depends more on their cognitive function than on whether they hear voices.

How Psychosis Develops: The Years Before the First Episode

Psychosis almost never arrives overnight. By the time someone is hearing voices or holding a fixed delusional belief, the process has usually been building for months, sometimes years. Most first episodes land in the teens and early twenties -- late teens to early twenties for young men, a few years later for young women. That timing is not random. It overlaps exactly with the period when the brain is pruning and rewiring the prefrontal circuits that keep thinking organized.

The phase before the first frank episode is called the prodrome, and it rarely looks dramatic. What parents notice is a kid who used to be social pulling back into their room. Grades slipping. Sleep flipping to all night, then all day. A flatness where there used to be energy. Then smaller, stranger things: a sense that something has changed, that other people might be talking about them, that ordinary events carry a hidden meaning. None of this is yet a diagnosable psychotic disorder. But it's the smoke, and the smoke is where you want to be paying attention.

We have a name for that smoke: clinical high risk (sometimes called the at-risk mental state). These are young people with attenuated symptoms -- the volume turned partway up, not all the way. Not everyone at clinical high risk goes on to develop a psychotic disorder. The best meta-analyses put conversion at roughly 20% within two years and around a third within three. That cuts both ways. It means most of these kids do not convert, so we never label someone with a disease they don't have. And it means this is a genuine window, the way prediabetes is a window before diabetes: the trajectory isn't fixed yet, and what happens during it matters.

How I talk to patients and families about it

The fear in the room is always the same, even when nobody says it out loud: does this mean schizophrenia? So I name it first. What I tell families is that we are not diagnosing schizophrenia, we are watching a brain that's under some strain during a vulnerable stretch of development, and our whole job is to keep that strain low while we see which way things go.

I avoid the word "psychotic" as a label for the person. Symptoms can be psychotic; people are not. I describe what we're seeing in plain terms -- "your sleep has been off and your thoughts have felt harder to trust lately" -- because a teenager who feels described, not diagnosed, is a teenager who keeps coming back. The single most important thing in this phase is that they don't disappear from care. Everything else depends on it.

And I'm honest about what we can and can't predict. Pretending we know exactly who will convert is dishonest, and kids smell it. What I can say with confidence is that the things that protect the brain here are the same things that protect it anyway, and the things that raise the risk are things we can actually do something about.

The things that make it worse -- and most of them are modifiable

This is the part of the conversation I refuse to soften, because the stakes are too high. A handful of substances don't just correlate with psychosis. They push a vulnerable brain across the line.

• Cannabis is the big one. Adolescent, frequent, high-potency use is the most preventable risk factor for psychosis we know of. The EU-GEI study (Di Forti, 2019) found that daily users of high-potency cannabis had roughly five times the odds of a psychotic disorder compared to people who never used. The risk scales with potency and frequency, and it hits hardest in exactly the age group sitting in my office. Today's flower and concentrates are not the cannabis of the 1990s, and a brain already showing prodromal signs is the worst possible brain to be loading with high-THC product.
• Methamphetamine and cocaine. Stimulant-induced psychosis is not just a bad night that clears by morning. A meaningful share of people who have a meth-induced psychotic episode go on to a persistent psychotic disorder. For someone already at clinical high risk, a stimulant binge can be the shove that tips the whole system over.
• Sleep deprivation. Pull an all-nighter and a healthy brain gets paranoid and starts misreading the world. In a vulnerable one, lost sleep isn't a lifestyle issue, it's a trigger. Protecting sleep is one of the most underrated psychiatric interventions there is.

I frame it for patients the way I'd frame a peanut allergy. For most people a handful of peanuts is nothing. For the wrong person it's an emergency. High-potency cannabis and stimulants are fine-to-fatal depending on the brain you bring to them, and a brain showing early warning signs has already told us which kind it is.

The things that protect

The flip side is genuinely hopeful, and it's not exotic. The most protective factors in this window are ordinary structure.

• A structured daily life. A predictable rhythm -- consistent wake and sleep times, regular meals, a reason to be somewhere each day -- does real work. Disorganization in the day feeds disorganization in thought. A scaffold on the outside helps hold things together on the inside while the brain is shaky.
• Staying in school or work. The instinct, for the family and sometimes the clinician, is to pull a struggling young person out of everything so they can "rest." That's usually the wrong move. Continued education and supported employment are among the strongest predictors of good long-term function, which is why coordinated specialty care builds them in rather than treating them as something to get to later. Keeping a foothold in normal life is protective. Losing it tends to accelerate the slide.
• Connection and not being alone with it. Isolation is both a symptom and an accelerant. Keeping a person tethered -- to family, to a few friends, to a clinician they trust -- buys time and catches changes early.

None of this replaces clinical care, and at clinical high risk the evidence does not support starting antipsychotics in everyone. What it supports is exactly this: close monitoring, treating any depression or anxiety that's present, hard work on sleep and substances, and keeping the person anchored in their life. Then, if symptoms do cross the line into a first episode, we're already in the room and the duration of untreated psychosis is short instead of long. Which is the whole game, as the next section explains.

First-Episode Psychosis: Why Early Intervention Is Critical

First-episode psychosis (FEP) is one of the most important windows of opportunity in all of psychiatry. The duration of untreated psychosis (DUP) -- the time from onset of psychotic symptoms to initiation of adequate treatment -- is one of the strongest predictors of long-term outcome.

What the research shows:

• Shorter DUP is associated with better treatment response, greater likelihood of remission, preserved cognitive function, better social and occupational outcomes, and reduced risk of treatment resistance
• Longer DUP is associated with poorer response to antipsychotic medication, greater negative symptom burden, more cognitive decline, and poorer overall prognosis
• The RAISE (Recovery After an Initial Schizophrenia Episode) study demonstrated that coordinated specialty care for FEP -- combining low-dose antipsychotic medication, individual therapy (CBT), family education and support, and supported employment and education -- produced significantly better outcomes than treatment as usual

The average DUP in the United States is approximately 74 weeks -- nearly a year and a half of untreated psychosis. This is unacceptable and represents a failure of our mental health system to identify and treat psychosis early. Every week of untreated psychosis matters.

Warning signs that should prompt urgent evaluation:

• Social withdrawal and isolation that is new or worsening
• Decline in school or work performance
• Unusual or bizarre beliefs or fears
• Suspiciousness or paranoia
• Hearing or seeing things others do not
• Decline in personal hygiene
• Flat or inappropriate emotional responses
• Confused or disorganized speech
• Sleep disturbance with increasing agitation

Most First-Break Psychosis Doesn't Turn Out to Be Schizophrenia

This is the part families are rarely told at the first presentation, and it changes how the first months should be handled.

When someone presents with a first psychotic episode, the diagnosis that eventually fits is frequently not schizophrenia. Murrie and colleagues pooled 50 studies covering 40,783 people in 2020 and followed what happened after substance-induced, brief and atypical psychoses. About 25% of substance-induced psychoses went on to a schizophrenia diagnosis (95% CI 18 to 35), and about 36% of brief, atypical and not-otherwise-specified psychoses did (95% CI 30 to 43).

Read the other way round: roughly three quarters of substance-induced first episodes, and roughly two thirds of brief and atypical ones, did not become schizophrenia.

The substance involved mattered more than anything else. Cannabis-induced psychosis carried the highest transition rate at 34% (95% CI 25 to 46), followed by hallucinogens at 26% and amphetamines at 22%. Opioid, alcohol and sedative-induced psychoses ran lower, at 12%, 10% and 9%.

Source: Murrie B, Lappin J, Large M, Sara G. Schizophr Bull. 2020;46(3):505-516. 50 studies, 79 estimates, 40,783 people.

What that means for the first six months

I have evaluated and treated hundreds of first-episode presentations. In a substantial share of them, the diagnosis that eventually fit was neither schizophrenia nor bipolar disorder. That isn't something I take credit for, and it isn't a claim about treatment working unusually well. It's what the natural history predicts when a first presentation is characterized carefully instead of labeled quickly.

What it does require is a willingness to hold the diagnosis open while treating the symptoms in front of you. Psychosis needs treating on presentation regardless of what is causing it. The diagnostic label, though, carries consequences that are hard to reverse: insurance records, self-concept, family expectations, and in some cases decades of unnecessary medication. Applying "schizophrenia" or "bipolar disorder" at week two, when the evidence says the majority of these presentations resolve into something else, is a decision with a real cost attached.

The practical version looks like this:

• Treat the psychosis now, name it later. Antipsychotic treatment starts on clinical need, and duration of untreated psychosis is the thing worth minimizing. The diagnostic formulation can stay provisional while that happens.
• Take the substance history seriously and repeatedly. Cannabis is the highest-risk exposure in this data, and use is frequently under-reported at first contact. This is the part of the assessment my own cannabis research makes me least willing to rush.
• Look hard for mood. Psychotic depression and bipolar disorder with psychotic features are treatable conditions with different medication paths, and both are missed when psychosis dominates the presentation.
• Rule out the medical causes. Delirium, autoimmune encephalitis, thyroid disease, B12 deficiency, temporal lobe epilepsy and prescribed medications all produce psychotic presentations.
• Re-review at three and six months. Diagnosis in early psychosis is a moving picture, and a formulation written at admission should be revisited rather than inherited.

Where the picture does consolidate into schizophrenia, that is worth recognizing promptly too, because it changes the treatment plan and the case for early clozapine consideration. Holding a diagnosis open isn't the same as avoiding it.

Antipsychotic Medications: First-Generation vs. Second-Generation

First-Generation (Typical) Antipsychotics

Developed in the 1950s, first-generation antipsychotics (FGAs) revolutionized the treatment of schizophrenia by blocking dopamine D2 receptors. They are effective for positive symptoms but carry significant neurological side effects.

Key FGAs:

• Haloperidol (Haldol): High-potency, effective for acute psychosis and agitation. Available in long-acting injectable (decanoate) form. Higher risk of EPS.
• Chlorpromazine (Thorazine): Low-potency, more sedating, lower EPS risk but more anticholinergic and metabolic effects.
• Fluphenazine: Available as long-acting injectable (decanoate). Commonly used for maintenance treatment.

Side effects of FGAs: Extrapyramidal symptoms (acute dystonia, akathisia, parkinsonism), tardive dyskinesia (involuntary movements, particularly facial, with long-term use; potentially irreversible), neuroleptic malignant syndrome (rare but life-threatening: fever, rigidity, autonomic instability), and prolactin elevation (causing breast enlargement, lactation, menstrual irregularities, sexual dysfunction).

Second-Generation (Atypical) Antipsychotics

Developed starting in the 1990s, second-generation antipsychotics (SGAs) block both dopamine D2 and serotonin 5-HT2A receptors. They have lower EPS risk but introduced a new set of metabolic concerns.

Key SGAs:

• Risperidone (Risperdal): Well-studied, effective, available as long-acting injectable (Risperdal Consta). Dose-dependent EPS and prolactin elevation.
• Olanzapine (Zyprexa): Highly effective but carries the highest metabolic risk (weight gain averaging 10-15 lbs in the first year, diabetes risk, dyslipidemia). Available as long-acting injectable (Zyprexa Relhypv).
• Quetiapine (Seroquel): Sedating, useful when insomnia is prominent. Lower EPS risk. Metabolic effects moderate.
• Aripiprazole (Abilify): Partial dopamine agonist with a favorable metabolic profile (weight-neutral or minimal gain). Available as long-acting injectable (Abilify Maintena, Aristada). May cause akathisia.
• Ziprasidone (Geodon): Weight-neutral. Requires QTc monitoring (cardiac conduction). Must be taken with food for absorption.
• Lurasidone (Latuda): Favorable metabolic profile. Also effective for bipolar depression. Must be taken with food.
• Cariprazine (Vraylar): Partial dopamine agonist with emerging evidence for efficacy against negative symptoms -- a significant advantage if confirmed, as most antipsychotics do little for negative symptoms.
• Paliperidone (Invega): Active metabolite of risperidone. Available as monthly and 3-monthly long-acting injectable (Invega Sustenna, Invega Trinza). Useful for adherence challenges.

Long-Acting Injectable Antipsychotics (LAIs)

LAIs are administered by injection every 2-12 weeks rather than taken daily by mouth. They eliminate the daily adherence burden -- a critical advantage given that medication non-adherence is the single biggest risk factor for relapse in schizophrenia. Studies consistently show that LAIs reduce relapse and hospitalization rates compared to oral antipsychotics, primarily by ensuring consistent medication delivery. I recommend LAIs for any patient who has experienced relapse due to non-adherence, who prefers the convenience of less frequent dosing, or who wants to eliminate the daily reminder of their illness.

Clozapine: The Only Antipsychotic Proven in Treatment-Resistant Schizophrenia

Clozapine (Clozaril) stands alone in the antipsychotic armamentarium. It is the only antipsychotic proven to be effective in treatment-resistant schizophrenia -- defined as failure to respond to at least two adequate trials of other antipsychotics. Approximately 30% of patients with schizophrenia are treatment-resistant, and among these, 30-60% will respond to clozapine.

Clozapine is also the only antipsychotic proven to reduce suicide risk in schizophrenia (the InterSePT trial demonstrated a 26% reduction in suicidal behavior). Given that approximately 5% of individuals with schizophrenia die by suicide, this property is clinically significant.

Why is clozapine underused? Despite its superior efficacy and anti-suicidal properties, clozapine is significantly underutilized. In a Veterans Affairs cohort of 14,620 patients with schizophrenia that I analyzed with colleagues, 246 received clozapine, which is 1.7%. Rates in some other countries run substantially higher. The primary barriers are the monitoring requirement for agranulocytosis (a dangerous drop in white blood cells that occurs in 1-2% of patients, requiring weekly blood draws for the first 6 months, then biweekly, then monthly), prescriber unfamiliarity (many psychiatrists have limited experience prescribing and managing clozapine), side effect burden (significant weight gain, sedation, drooling, constipation, metabolic effects, seizure risk at high doses), and the REMS (Risk Evaluation and Mitigation Strategy) program that requires registration of prescribers, pharmacies, and patients.

What our clozapine monitoring study found

I published on this question with Mark Olfson, Christoph Correll and Erica Duncan in the Journal of Clinical Psychiatry in 2017. We analyzed antipsychotic prescribing records in the Veterans Integrated Service Network 7 database between 1999 and 2012, and asked what the 2015 FDA monitoring change would have meant for the patients in it.

The 2015 change lowered the absolute neutrophil count threshold for treatment interruption from 1,500/µL to 1,000/µL, and removed white blood cell count thresholds from the algorithm entirely.

• Of 14,620 patients with schizophrenia, 246 received clozapine, or 1.7%.
• No agranulocytosis was observed anywhere in the study period.
• Under the former monitoring rules, 5 of 160 patients starting clozapine (3.1%, 95% CI 0.43-5.83) qualified for treatment interruption in their first year.
• Under the 2015 rules, that figure was 1 patient, 0.6%.
• Under the former rules, hematologic events occurred at a similar rate in patients taking and not taking clozapine.

The study evaluated the effect of a policy change that had already been made; it did not cause it. What it quantified is that most first-year clozapine interruptions under the old algorithm were being triggered by counts that carried no evident clinical danger, and that the revised thresholds substantially reduce them.

My position follows from the data rather than from enthusiasm for the drug. Clozapine is underused, the monitoring burden is a real barrier but a smaller one than it was, and patients who have failed two adequate antipsychotic trials should be offered it rather than cycled through a third and fourth.

Metabolic Monitoring: A Critical and Often Neglected Component

People with schizophrenia have a life expectancy 15-20 years shorter than the general population, and the leading cause of this premature mortality is cardiovascular disease -- not suicide or violence as commonly assumed. Antipsychotic medications, particularly SGAs, contribute to cardiovascular risk through metabolic side effects.

My JAMA Network Open study on antipsychotic prescribing patterns highlighted that metabolic monitoring is frequently inadequate in clinical practice. Many patients on antipsychotics do not receive recommended baseline and follow-up monitoring of fasting glucose, lipids, weight, waist circumference, and blood pressure.

Recommended monitoring schedule:

I monitor these parameters systematically in all patients on antipsychotic medications and intervene early when metabolic abnormalities develop -- whether through medication switching, dose reduction, lifestyle interventions, or addition of metabolic medications (metformin, statins) when needed.

Cannabis and Psychosis: A Major Public Health Concern

The relationship between cannabis use and psychotic disorders is one of my primary areas of research. The evidence linking cannabis to psychosis is substantial and growing.

Key findings:

• Cannabis use is associated with a 2-4 fold increased risk of developing a psychotic disorder
• The risk is dose-dependent: daily use of high-potency cannabis (high THC content) carries the highest risk
• Adolescent cannabis use carries particularly high risk, as the developing brain is more vulnerable
• Cannabis can precipitate psychotic episodes in individuals with genetic vulnerability to schizophrenia
• Continued cannabis use after a first psychotic episode worsens outcomes -- more frequent relapses, longer hospitalizations, and poorer medication response
• A 2019 Lancet Psychiatry study estimated that daily use of high-potency cannabis accounts for approximately 12% of new cases of psychosis across Europe, and up to 30% in cities like Amsterdam and London where high-potency cannabis is prevalent

This is critically important in the context of cannabis legalization and increasing THC potency. The cannabis products available today are dramatically more potent than those available 20-30 years ago -- THC concentrations have increased from approximately 4% to 15-25% in flower, and concentrates can exceed 80-90% THC.

For fuller coverage of this topic, see my detailed guide on Cannabis and Psychosis.

The Recovery Model: Beyond Symptom Reduction

Modern schizophrenia treatment has shifted from a purely symptom-focused model to a recovery-oriented approach. Recovery does not necessarily mean cure or complete symptom remission -- it means living a meaningful, satisfying life despite the presence of illness.

Key components of recovery-oriented care:

• Medication as a foundation, not the whole treatment: Antipsychotic medication controls positive symptoms and reduces relapse risk, but medication alone is insufficient for full recovery. It must be combined with psychosocial interventions.
• Cognitive Behavioral Therapy for Psychosis (CBTp): Adapted CBT that helps patients examine and challenge delusional beliefs, develop coping strategies for hallucinations, and manage distress associated with psychotic symptoms. Evidence supports CBTp as an adjunct to medication.
• Supported employment and education: The Individual Placement and Support (IPS) model places individuals directly into competitive employment with ongoing support. IPS consistently outperforms traditional vocational rehabilitation, with employment rates of 55-65% vs. 20-25%.
• Family psychoeducation: Family-based interventions that provide education about schizophrenia, improve communication, reduce expressed emotion (hostility, criticism, overinvolvement), and teach problem-solving skills. These interventions reduce relapse rates by approximately 50% compared to medication alone.
• Peer support: Connection with individuals who have lived experience with psychotic disorders provides hope, practical strategies, and validation that recovery is possible.
• Social skills training: Structured programs that teach conversation skills, assertiveness, community living skills, and workplace behaviors.
• Cognitive remediation: Targeted interventions to improve cognitive function (attention, memory, executive function) through computer-based exercises and strategy training.

Family Education: What Families Need to Know

Schizophrenia affects not just the individual but the entire family. Families often experience grief, confusion, frustration, and burnout. Providing families with accurate information and support is an essential component of treatment.

Key messages for families:

• Schizophrenia is a brain-based illness, not a choice or a failure of parenting
• Medication adherence is critical -- stopping medication is the most common cause of relapse
• Recovery is possible but may look different from what you expect -- meaningful recovery does not require complete symptom elimination
• Stress management matters -- high levels of family conflict ("expressed emotion") increase relapse risk
• Substance use (especially cannabis) worsens outcomes and should be strongly discouraged
• Early warning signs of relapse (sleep changes, increased isolation, unusual beliefs) should prompt immediate contact with the treatment team
• Self-care for caregivers is essential -- you cannot support your family member if you are burned out
• NAMI (National Alliance on Mental Illness) offers excellent family support programs

My Approach to Psychotic Disorders

At Integrative Psych in Chelsea, Manhattan, I bring my research background at Columbia University directly to clinical practice. My JAMA Network Open work on antipsychotic prescribing in youth shaped how I think about indication and dose, and I hold my own prescribing to the standard that study applied to everyone else's: a clear diagnostic indication, a defensible dose, and metabolic monitoring that actually happens. I have evaluated and treated hundreds of first-episode presentations, and I have published on clozapine monitoring in treatment-resistant schizophrenia. My cannabis research makes me particularly attuned to the role of substance use in psychotic disorders and the importance of addressing it as part of treatment.

Key elements of my approach:

• Provisional diagnosis, held open: Most first-break psychosis does not turn out to be schizophrenia. Psychotic symptoms can occur in bipolar disorder, severe depression, substance-induced psychosis, medical conditions, and brief psychotic disorder. Accurate diagnosis determines treatment.
• Evidence-based medication selection: I choose antipsychotics based on efficacy evidence, side effect profiles, patient preferences, and practical considerations (adherence history, metabolic risk, desire for LAI).
• Systematic metabolic monitoring: Following APA/ADA guidelines for weight, glucose, lipids, and cardiovascular risk assessment -- something my research showed is too often neglected.
• Clozapine advocacy: For treatment-resistant patients, I actively offer and manage clozapine rather than cycling through additional failed antipsychotic trials.
• Substance use assessment: Detailed evaluation of cannabis, alcohol, and other substance use, with integrated treatment when substance use disorders co-occur. Cannabis carries the highest transition risk to schizophrenia of any substance-induced psychosis, at 34%.
• Recovery orientation: Medication management is one component of a treatment plan that also includes therapy, family support, social skills development, and vocational or educational support.

Frequently Asked Questions

What is first-episode psychosis and why is early treatment critical?

First-episode psychosis (FEP) refers to the first time a person experiences a psychotic episode -- a break from reality involving hallucinations, delusions, or severely disorganized thinking. Early intervention is critical because research consistently shows that the duration of untreated psychosis (DUP) is one of the strongest predictors of long-term outcome. Shorter DUP is associated with better treatment response, greater symptom remission, improved cognitive function, and better social and occupational functioning. Coordinated specialty care programs for FEP (like NAVIGATE) that combine low-dose antipsychotic medication, individual therapy, family education, and supported employment produce significantly better outcomes than treatment as usual.

Does a first psychotic episode mean schizophrenia?

Frequently not. In a meta-analysis of 50 studies covering 40,783 people, 25% of substance-induced psychoses went on to a schizophrenia diagnosis and 36% of brief, atypical or not-otherwise-specified psychoses did. That means roughly three quarters of substance-induced first episodes and two thirds of brief and atypical ones did not become schizophrenia. Psychosis needs treating on presentation regardless of cause, but the diagnostic label is worth holding provisional and revisiting at three and six months.

How much does the 2015 FDA clozapine monitoring change matter?

Substantially, on the evidence. In a Veterans Affairs cohort of 14,620 patients with schizophrenia, 246 received clozapine, which is 1.7%, and no agranulocytosis was observed during the study period. Under the former monitoring rules, 5 of 160 patients starting clozapine qualified for treatment interruption in their first year, or 3.1%. Under the 2015 rules that figure was 1 patient, 0.6%. Most first-year interruptions under the old algorithm were being triggered by counts that carried no evident clinical danger.

What is the difference between first-generation and second-generation antipsychotics?

First-generation (typical) antipsychotics (haloperidol, chlorpromazine, fluphenazine) primarily block dopamine D2 receptors and are effective for positive symptoms but carry higher risk of extrapyramidal side effects (muscle stiffness, tremor, restlessness) and tardive dyskinesia (involuntary movements with long-term use). Second-generation (atypical) antipsychotics (risperidone, olanzapine, quetiapine, aripiprazole, ziprasidone, lurasidone, cariprazine, clozapine) block both dopamine and serotonin receptors, have lower risk of extrapyramidal effects, but carry higher risk of metabolic side effects (weight gain, diabetes, high cholesterol). Overall efficacy for positive symptoms is similar between the two generations, with the exception of clozapine, which is uniquely effective for treatment-resistant schizophrenia.

What is clozapine and when is it used?

Clozapine (Clozaril) is the most effective antipsychotic medication, uniquely proven to work in treatment-resistant schizophrenia (when at least two other antipsychotics have failed). It is also the only antipsychotic proven to reduce suicide risk in schizophrenia. Despite its superior efficacy, clozapine is underutilized due to its monitoring requirements -- it carries a risk of agranulocytosis (dangerous drop in white blood cells), requiring regular blood monitoring. Dr. Sultan co-authored research on clozapine and FDA monitoring requirements with Dr. Duncan at Emory University, examining how to improve access to this life-saving medication while maintaining safety.

Can cannabis cause psychosis?

There is strong evidence linking cannabis use to psychotic disorders, particularly with high-potency THC products and use during adolescence. Cannabis use is associated with a 2-4 fold increased risk of developing a psychotic disorder, and the risk increases with frequency of use, potency of THC, and younger age of onset. For individuals with genetic vulnerability to psychosis, cannabis can trigger the onset of schizophrenia. Dr. Sultan's major research area is the relationship between cannabis and psychiatric outcomes, and he has published extensively on this topic. See his detailed guide on Cannabis and Psychosis.

Can people with schizophrenia recover?

Yes. While schizophrenia is a chronic condition that typically requires ongoing treatment, many people with schizophrenia can achieve meaningful recovery. Studies of long-term outcomes suggest that approximately 20-25% of individuals achieve full symptom remission, 40-50% show significant improvement with some residual symptoms, and modern recovery-oriented approaches focus on functional recovery (living independently, working, maintaining relationships) rather than just symptom reduction. Early intervention, consistent antipsychotic treatment, psychosocial support, and avoidance of substances (particularly cannabis and stimulants) all improve the likelihood of favorable outcomes.

What are the metabolic side effects of antipsychotics and how are they monitored?

Antipsychotic medications, particularly second-generation antipsychotics, can cause significant metabolic side effects including weight gain, elevated blood sugar (risk of type 2 diabetes), dyslipidemia (elevated cholesterol and triglycerides), and metabolic syndrome. These effects increase cardiovascular disease risk, which is a leading cause of premature death in schizophrenia. Monitoring should include baseline and periodic measurements of weight/BMI, waist circumference, fasting glucose/HbA1c, fasting lipid panel, and blood pressure. Dr. Sultan's JAMA research highlighted that metabolic monitoring is frequently inadequate in clinical practice, leading to preventable cardiovascular morbidity.

References

• Murrie B, Lappin J, Large M, Sara G. Transition of substance-induced, brief, and atypical psychoses to schizophrenia: a systematic review and meta-analysis. Schizophr Bull. 2020;46(3):505-516. PMID 31618428
• Sultan RS, Olfson M, Correll CU, Duncan EJ. Evaluating the effect of the changes in FDA guidelines for clozapine monitoring. J Clin Psychiatry. 2017;78(8):e933-e939. PMID 28742291
• Sultan RS, Wang S, Crystal S, Olfson M. Antipsychotic treatment among youths with attention-deficit/hyperactivity disorder. JAMA Netw Open. 2019;2(7):e197850. PMID 31348506
• Sultan RS, Zhang AW, Olfson M, Kwizera MH, Levin FR. Nondisordered cannabis use among US adolescents. JAMA Netw Open. 2023;6(5):e2311294. PMID 37133862
• Kane JM, Robinson DG, Schooler NR, et al. Comprehensive versus usual community care for first-episode psychosis: 2-year outcomes from the NIMH RAISE Early Treatment Program. Am J Psychiatry. 2016;173(4):362-372. PMID 26481174

Further Reading

• Cannabis and Psychosis: Complete Guide
• Off-Label Antipsychotic Prescribing in Children
• Psychiatric Medication Management
• Bipolar Disorder Treatment